Different mechanisms for benefit and risk of coronary heart disease and stroke in early postmenopausal women: A hypothetical explanation

Menopause

Volumn 18, Issue 2, 2011, Pages 237-240

  Lobo, Rogerio A ^a   Clarkson, Tom B ^b  

^a Howard Hughes Medical Institute   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Coronary heart disease; Estrogen; Hypothesis; Stroke; Thrombosis; Younger postmenopausal women

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; ORAL CONTRACEPTIVE AGENT;

AGE DISTRIBUTION; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; CORONARY RISK; DISEASE PREDISPOSITION; EARLY MENOPAUSE; ESTROGEN THERAPY; HEART INFARCTION; HUMAN; HYPOTHESIS; ISCHEMIC HEART DISEASE; NONHUMAN; PATENT FORAMEN OVALE; POSTMENOPAUSE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STROKE; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ATHEROSCLEROSIS; CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; POSTMENOPAUSE; RISK; STROKE; THROMBOSIS;

EID: 79951567296     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181e9e538     Document Type: Review

References (46)

1. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
2. Clarkson TB, Mehaffey MH. Coronary heart disease of females: lessons learned from nonhuman primates. Am J Primatol 2009;71:785-793.
3. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. JAMA 1998;280:605-613. (Pubitemid 28502636)
4. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
5. Grodstein F, Manson J, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health 2006;15:35-44. (Pubitemid 43192860)
6. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477. (Pubitemid 46556472)
7. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534. (Pubitemid 36951364)
8. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357-365. (Pubitemid 43244325)
9. Salpeter S. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004;19: 791-804. (Pubitemid 38951954)
10. Henderson BE, Paganini-Hill A, Ross RK. Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol 1988;159:312-317.
11. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-1775.
12. Lobo RA. Evaluation of cardiovascular event rates with hormone therapy in healthy postmenopausal women: results from four large clinical trials. Arch Intern Med 2004;164:48-84.
13. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-1811. (Pubitemid 29266405)
14. Clarkson TB. The new conundrum: do estrogens have any cardiovascular benefits? Int J Fertil 2002;47:61-68. (Pubitemid 34309540)
15. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005;308:1583-1587. (Pubitemid 40807497)
16. Karas RH. Mechanisms of action of estrogen on the cardiovascular system. In: Lobo RA, ed. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects, 3rd ed. Burlington, MA: Elsevier, 2007:453-469.
17. Clarkson TB, Kaplan JR. Stage of reproductive life, atherosclerosis progression and estrogen effects on coronary artery atherosclerosis. In: Lobo RA, ed. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects, 3rd ed. Burlington, MA: Elsevier, 2007:509-528.
18. Heistad DD. Unstable coronary-artery plaques. N Engl J Med 2003;349: 2285-2287. (Pubitemid 37509734)
19. Towfighi A, Ovbiagele B. Persistent and growing sex disparity in midlife stroke prevalence rates in the United States. Paper presented at: International Stroke Conference; February 24-28, 2010; San Antonio, TX.
20. Bushnell CD. Stroke in women: risk and prevention throughout the life-span. Neurol Clin 2008;26:1161-1176.
21. Godfrey JR, Sacco RL. Stroke and the effects of HT. J Womens Health 2009;18:13-18.
22. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G. Time to review all the evidence for hormone replacement therapy. JAMA 2003; 289:2673-2684.
23. Hendrix SL, Wassertheil-Smoller S. Effects of conjugated estrogen on stroke in the Women's Health Initiative. Circulation 2006;113: 2425-2434. (Pubitemid 43948050)
24. Sare GM, Gray LJ, Bath PMW. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J 2008;16:2031-2041.
25. Lobo RA. The risk of stroke in postmenopausal women receiving hormonal therapy. Climacteric 2009;12:81-85.
26. Grodstein F, Manson JE, Stampfer MJ, Rexrode K. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med 2008;168:861-866. (Pubitemid 351620088)
27. Schwartz SM, Siscovick DS, Longstreth WT, et al. Use of low-dose oral contraceptives and stroke in young women. Ann Intern Med 1997;127: 596-603.
28. Glagov S, Bassiouny HS, Masawa N, Sakaguchi Y, Giddens DP, Zarins CK. Cerebrovascular disease: a pathologist's view. In: Fuster V ed. Syndromes of Atherosclerosis: Correlations of Clinical Imaging and Pathology. Armonk, NY: Futura, 1996:161-180.
29. Clarkson TB, Anthony MS, Wagner JD. A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys. J Clin Endocrinol Metab 2001;86:5396-5404. (Pubitemid 33070266)
30. Clarkson TB, Anthony MS, Mikkola TS, St Clair RW. Comparison of tibolone and conjugated equine estrogens effects on carotid artery atherosclerosis of postmenopausal monkeys. Stroke 2002;11:2700-2703. (Pubitemid 35266444)
31. Caplan LR, Gorelick PB, Hier DB. Race, sex and occlusive cere-brovascular disease: a review. Stroke 1986;17:648-655. (Pubitemid 16066533)
32. Postiglione A, Nappi A, Brunetti, et al. Relative protection from cerebral atherosclerosis of young patients with homozygous familial hyper-cholesterolemia. Atherosclerosis 1991;90:23-30.
33. Viscoli CM, Brass LM, Kernan WN, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345: 1243-1249. (Pubitemid 34951488)
34. Prentice RL, Langer R, Stefanick ML, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 2005;162:404-414. (Pubitemid 41191425)
35. LeMaitre RN, Weiss NS, Smith NL, et al. Esterified estrogen and conjugated equine estrogen and the risk of incident myocardial infarction and stroke. Arch Intern Med 2006;166:399-404.
36. Pezzini A, Grassi M, Iacoviello L, et al. Inherited thrombophilia and stratification of ischaemic stroke risk among users of oral contraceptives. J Neurol Neurosurg Psychiatry 2007;78:271-276. (Pubitemid 46579665)
37. Aznar J, Mira Y, Vaya A, et al. Factor V Leiden and prothrombin G20210A mutations in young adults with cryptogenic ischemic stroke. Thromb Haemost 2004;91:1031-1034. (Pubitemid 38647509)
38. Slooter AJ, Rosendaal FR, Tanis BC, et al. Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. J Thromb Haemost 2005;3:1213-1217. (Pubitemid 41725244)
39. Martinelli L, Battaglioli T, Burgo I, et al. Oral contraceptive use, thrombophilia, and their interaction in young women with ischemic stroke. Haematologia 2006;91:844-847. (Pubitemid 44014558)
40. Pruissen DM, Slooter AJ, Rosendaal FR, et al. Coagulation factor XIII gene variation, oral contraceptives, and risk of ischemic stroke. Blood 2008;111:1282-1286. (Pubitemid 351213411)
41. Urbanus RT, Siegerink B, Roest M, et al. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study; a case-control study. Lancet Neurol 2009; 8:998-1005.
42. Greep NC, Tobis J, Cua B, Liebeskind D. The role of patent foramen ovale (PFO) in ischemic strokes among postmenopausal women on hormone replacement (HRT). Menopause 2009;16:1236-S-4.
43. Krause DM, Duckles SP, Pelligrino DA. Influence of sex steroid hormones on cerebrovascular function [review]. J Appl Physiol 2006;101: 1252-1261. (Pubitemid 44497571)
44. Gibson EL, Gray LJ, Murphy SP, Bath PM. Estrogens and experimental ischemic stroke: a systematic review. J Cereb Blood Flow Metab 2006;26:1103-1113. (Pubitemid 44268172)
45. Zhang QG, Raz L, Wang R, et al. Estrogen attenuates ischemic oxidative damage via an estrogen receptor >-mediated inhibition of NALDPH oxidase activation. J Neurosci 2009;44:13823-13836.
46. Lisabeth LD, Beiser AS, Brown DL, et al. Age at natural menopause and risk of ischemic stroke: the Framingham Heart Study. Stroke 2009;40: 1044-1049.